Discover the full directors' dealings record of LifeStance Health Group, Inc., a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, LifeStance Health Group, Inc. has logged 1 public disclosures. Market capitalisation: €2.7bn. The latest transaction was filed on 14 May 2026 — Cession. Among the most active insiders: TPG GP A, LLC. The full history is free.
0 of 0 declarations
LifeStance Health Group, Inc. (NASDAQ: LFST) is a United States-based behavioral health company focused on outpatient mental healthcare. Founded in 2017, the company was built to address the growing need for accessible psychiatric and therapy services through a hybrid delivery model that combines virtual visits with in-person care. Its corporate headquarters is in Scottsdale, Arizona, United States. As a NASDAQ-listed name, LifeStance sits in the healthcare growth segment, where investors typically focus on network expansion, clinician recruitment, utilization trends and the path toward durable profitability. LifeStance operates a national platform serving children, adolescents and adults across a broad range of mental health conditions. Its core services include psychiatry, psychology, psychotherapy and related outpatient behavioral health treatment. The company’s model is centered on a large clinician network and a geographically distributed center footprint, enabling patients to choose between telehealth and office-based care. That flexibility is a key part of its value proposition, particularly in mental health, where continuity of care and ease of access can materially influence treatment adherence and patient outcomes. From a competitive standpoint, LifeStance is one of the larger outpatient mental healthcare providers in the United States. Its scale, multi-state presence and hybrid care infrastructure help differentiate it from smaller independent practices and from pure-play digital therapy providers. The company also benefits from referral relationships with primary care physicians, specialists, health systems and academic partners, which support patient acquisition and reinforce its regional market positions. In a fragmented industry, LifeStance’s integrated platform and national operating model are meaningful strategic assets. The company has a relatively short corporate history, but it has already gone through an important strategic evolution. After an aggressive buildout phase through de novo center openings and acquisitions, LifeStance shifted toward operational discipline and a more efficient physical footprint as virtual visits became a larger part of the care mix. That recalibration reflects management’s effort to balance growth with margin improvement and capital efficiency. Recent financial disclosures point to that transition: in 2025 results reported in early 2026, LifeStance highlighted double-digit revenue growth, positive net income, strong cash generation and a new $100 million share repurchase authorization. Geographically, LifeStance’s business is concentrated in the United States, with operations across more than 30 states and a broad center network. For French, Belgian and Swiss investors, LFST can be viewed as a thematic healthcare exposure tied to structural demand for mental health services, but with execution risk still linked to clinician supply, reimbursement dynamics, utilization rates and the company’s ability to sustain margin expansion while scaling.